{"id":107885,"date":"2025-12-10T12:32:28","date_gmt":"2025-12-10T11:32:28","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/julia-domingo-ceo-of-allox-in-addition-to-the-infrastructure-and-support-provided-by-the-pcb-it-is-very-positive-to-be-part-of-a-close-knit-community-from-which-you-can-learn\/"},"modified":"2025-12-11T09:01:43","modified_gmt":"2025-12-11T08:01:43","slug":"julia-domingo-ceo-of-allox-in-addition-to-the-infrastructure-and-support-provided-by-the-pcb-it-is-very-positive-to-be-part-of-a-close-knit-community-from-which-you-can-learn","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/julia-domingo-ceo-of-allox-in-addition-to-the-infrastructure-and-support-provided-by-the-pcb-it-is-very-positive-to-be-part-of-a-close-knit-community-from-which-you-can-learn\/","title":{"rendered":"J\u00falia Domingo, CEO of ALLOX: “In addition to the infrastructure and support provided by the PCB, it is very positive to be part of a close-knit community from which you can learn”"},"content":{"rendered":"

The biotechnology startup ALLOX<\/a> arrived at the Barcelona Science Park almost a year ago, and since then it has been advancing relentlessly in its mission to discover new drugs targeting therapeutic targets that are currently inaccessible with conventional treatments. Its innovative technology allows the identification and modulation of the allosteric sites of proteins, key regions that regulate how these proteins interact with others. Thanks to this, ALLOX can act with greater precision on the functions of proteins in the body, opening the door to the development of much more specific drugs.<\/strong><\/p>\n

Founded in 2023 as a spin-off of the Centre for Genomic Regulation (CRG) in Barcelona, with the support of Asabys Partners and CDTI Innovaci\u00f3n, ALLOX has created an innovative platform that combines experimental genetics, artificial intelligence, and energy-based models. Its goal is to turn what was once considered unattainable in medicine into reality: identifying allosteric sites, previously elusive, and transforming them into new therapeutic targets to develop more effective treatments.<\/p>\n

“Most of the allosteric therapies on the market are very good, but they were discovered entirely by chance. Where we make the difference is that we have a very direct and systematic way of detecting these allosteric sites in many proteins,” explains J\u00falia Domingo<\/strong>, CEO of ALLOX, in this interview during the latest edition of the Coffee Connection meeting. During the conversation, the researcher also highlighted the challenges of creating a company, such as identifying the right talent and finding the most suitable people to join the team and build a project together.<\/p>\n